

ANCO FAX News

Association of Northern California Oncologists
Post Office Box 151109, San Rafael, California 94915-1109
Voice: (415) 472-3960 • FAX: (415) 472-3961
execdir@anco-online.org • www.anco-online.org

Vol. 16, No. 15

August 11th, 2017

The *ANCO FAX News* focuses on ANCO's core activities—advocacy, clinical and professional education, and *Association* and membership news. While membership mailings and e-mail/FAX broadcasts continue, the *ANCO FAX News* summarizes this information in a regular forum of important news to members. Contact the ANCO office for additional information regarding any item published in the *ANCO FAX News*. Find the *ANCO FAX News* online at www.anco-online.org/pubs.html.

In this issue:

- Federal right-to-try legislation
- ANCO's 2017 Professional Education Meeting & 3Q2017 Hematologic Malignancies Updates
- ANCO Young Investigator Award

The *ANCO FAX News* is FAXed to Individual Member practices, and e-mailed to Group, Institutional, and Corporate (contacts) Members.

The next regular *ANCO FAX News* will be published on August 25th. Send your comments or contributions to ANCO, P.O. Box 151109, San Rafael, CA 94915-1109; Voice: (415) 472-3960; FAX: (415) 472-3961; execdir@anco-online.org.

The *ANCO FAX News* has information for every member of your practice or organization. Pass it along!

- Physician Members
- Nurses & Office Managers
- Office Staff
- Colleagues & Representatives

The *Association of Northern California Oncologists* (ANCO) is an association of hematologists/oncologists dedicated to promoting high professional standards of cancer care by providing a forum for the exchange of ideas, data, and knowledge.

The material contained in the *ANCO FAX News* is intended as general information for ANCO members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the *ANCO FAX News* may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in the *ANCO FAX News* should not be used as a substitute for such advice.

ADVOCACY

[Editor's Note: ANCO is a member of the Association of Community Cancer Centers (ACCC) and a state/regional affiliate of the American Society of Clinical Oncology (ASCO). ANCO and the Medical Oncology Association of Southern California (MOASC) are members of the California Medical Association's (CMA) Council on Legislation, House of Delegates, and specialty delegation. ANCO meets regularly with these and other organizations to discuss issues of importance to hematology/oncology practices and people living with cancer. We continually seek input from members on agenda items for these meetings. Send your issues to the ANCO office.]

ACCC, ASCO, ASH, COA, and National Legislative & Regulatory Issues

The *United States Senate* approved a “right-to-try” bill by unanimous consent that would authorize the use of unapproved drug therapies by terminally ill patients who have exhausted other treatment options and are unable to participate in ongoing clinical trials as long as the drugs have been tested in Phase I clinical trials and are continuing in further FDA research. The *House* is in August recess but may take up the bill in September. ASCO strongly supports increasing access to investigational new treatment options for patients with cancer, while raising serious concerns about recently proposed *Federal* “right to try” (RTT) legislation as well as enacted *State* RTT laws. Read ASCO’s full position statement on access to investigational drugs at www.asco.org/sites/new-www.asco.org/files/content-files/blog-release/documents/2017-Access-to-Investigational-Drugs-Position-Statement.pdf?et_cid=39110097&et_rid=1760459169&linkid=full+statement.

CMS has released its proposed CY2018 *Physician Fee Schedule (PFS)* and *Outpatient Prospective Payment System (OPPS)* rules. Read the proposed rule at www.federalregister.gov/documents/2017/07/20/2017-14883/medicare-program-hospital-outpatient-prospective-payment-and-ambulatory-surgical-center-payment; read the fact sheet at www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2017-Fact-Sheet-items/2017-07-13.html. Major changes

include a reduction in payments to hospitals participating in 340B under OPPS. Overall, physician payment rates will increase by .31% in CY2018 compared to CY2017, including an estimated 1% increase for radiation oncology. Read Bobbi Buell’s summary of the proposed rule at www.anco-online.org/BBMPFS2018Analysis.pdf.

CMS is readying a fraud prevention initiative that removes *Social Security Numbers* from Medicare cards to help combat identity theft and safeguard taxpayer dollars. The new cards will use a unique, randomly-assigned number called a *Medicare Beneficiary Identifier* (MBI) to replace the *Social Security-based Health Insurance Claim Number* (HICN) currently used on the Medicare card. CMS will begin mailing new cards in April 2018. For more information, visit the CMS *Social Security Removal Initiative* (SSNRI) website at www.cms.gov/medicare/ssnri/.

The *Medicare Quality Payment Program (QPP)*, established by the *Medicare Access and CHIP Reauthorization Act (MACRA)*, began on January 1st. This year is a transition year meaning you can “pick your pace” when implementing QPP in your practice. CMS has posted new resources to the QPP website to help clinicians successfully participate in the first year of the QPP. The new resources focus on support for small practices and alternative payment models (APMs). Visit qpp.cms.gov for more information. In addition, CMS is now accepting hardship exceptions from the QPP for the 2017 reporting year based on insufficient internet connectivity, extreme and uncontrollable circumstances, and lack of control over the availability of certified EHR technology. Learn more at qpp.cms.gov/about/hardship-exception.

CMS has issued a proposed rule that would make changes in the second year of the QPP. The proposed rule “aims to simplify the program, especially for small, independent, and rural practices.” Read the CMS fact sheet at qpp.cms.gov/docs/QPP_Proposed_Rule_for_

QPP_Year_2.pdf; read ASCO's summary at www.asco.org/advocacy-policy/asco-in-action/proposed-2018-qpp-rule-adds-flexibility-questions-medicare-part-b; and, read Bobbi Buell's analysis at www.anco-online.org/BBMIPS2018.pdf.

Unsure of your MIPS participation status? Clinicians can now use an interactive tool on the CMS *Quality Payment Program* website to determine if they should participate in MIPS.

Visit qpp.cms.gov > Check Now, enter your NPI and information will then be provided on whether or not you should participate in MIPS in 2017 and where to find resources.

CMS is encouraging physicians to sign up for the new CMS QPP listserv to stay up-to-date on new resources, upcoming milestones and deadlines, and CMS webinars on the QPP. To subscribe to the QPP listserv, go to qpp.cms.gov and select "Subscribe to Email Updates" at the bottom of the page.

ASCO is pleased to announce that its *Quality Oncology Practice Initiative* (QOPI) *Qualified Clinical Data Registry* (QCDR) is now available for CMS MIPS reporting effective July 1st. By using the QOPI QCDR for MIPS reporting, practices will be able to report on one measure for one patient in 2017 to avoid cuts to Medicare reimbursements in 2019. Express your interest in participating in the QOPI QCDR by e-mailing qopi@asoc.org. Once registration is officially open, practices will be contacted regarding the necessary steps to begin their on-boarding process. For more information, please visit www.instituteforquality.org/qopi/about/quality-reporting.

ASCO's series of webinars to guide oncology practices to successful quality reporting are available at www.asco.org/macra > MACRA Webinar Series. ASCO has developed a MACRA decision tree tool to help oncology practices find precise information on their QPP participation status at [\[quality-payment-program/macra-practice-tools/determine-status\]\(http://www.asco.org/practice-guidelines/billing-coding-reporting/macra-quality-payment-program/macra-practice-tools/determine-status\). For more information and access to ASCO's revamped QPP/MACRA toolkit, educational materials, and resources, go to \[www.asco.org/macra\]\(http://www.asco.org/macra\). ASH's updated MACRA webpage is at \[www.hematology.org/Clinicians/7427.aspx\]\(http://www.hematology.org/Clinicians/7427.aspx\).](http://www.asco.org/practice-guidelines/billing-coding-reporting/macra-</p>
</div>
<div data-bbox=)

ASH members can now sign up to report data for the Medicare MIPS through *Healthmonix's* MIPS PRO, a 2017 Qualified MIPS Registry. Learn more at healthmonix.com/mips-pro/.

The *American Medical Association* (AMA) has produced a new short video entitled *One Patient, One Measure, No Penalty: How to avoid a Medicare payment penalty with basic reporting*. The video and other AMA resources are available at www.ama-assn.org/qpp-reporting.

CMA's *Center for Economic Services* (CES) has published an update to its MACRA preparation checklist entitled *MACRA: What Should I Do Now to Prepare?* available at www.cmanet.org/macra.

CMA, MOASC, and State Legislative & Regulatory Issues

Sacramento can be a dangerous place for doctors. Many bills impacting medicine wind their way through the *Capitol* on their journey to the *Governor's* desk. And, many of these bills threaten the medical profession with the backing of powerful lobbyists and PACs. It's critical that **physicians have an advocate at work for them every day and who knows how to speak on their behalf.** That advocate is the *California Medical Association* (CMA). While physicians keep a close eye on their patients, CMA is keeping a close eye on those bills...and more. **Got payment delays? Feeling victimized by payers and overwhelmed by the process? Don't let the health plans mistreat you.** The CMA's *Center for Economic Services* (CES) has a team of reimbursement specialists available to assist ANCO's CMA members experiencing payment problems with third-party payers. For membership, please call (916) 551-2042; for reimbursement assistance, please call

CMA's *Reimbursement Helpline* at (888) 401-5911.

Forthcoming CMA webinars include:

- Assembly Bill 72: How to Challenge the Interim Payment of Out-of-Network Services at In-Network Facilities (September 27)

Contact CMA's member help center at (800) 786-4262 or memberservice@cmanet.org for more information. Register online at www.cmanet.org/events.

CMA Practice Resources (CPR) is a monthly e-mail bulletin from CMA's *Center for Economic Services* that is full of tips and tools to help physicians and their office staff improve practice efficiency and viability. Subscribing to CPR is free and open to anyone, but CMA membership is necessary to access the resources, toolkits, forms, and tools that are located on the members-only CMA website. Please visit www.cmanet.org/cpr to subscribe. The August 2017 edition includes:

- Medi-Cal postponing deactivation of inactive providers
- UnitedHealthcare plans to discontinue payment for consultation services
- CMS releases proposed Medicare physician fee schedule for 2018
- Survey finds nation's physicians not ready to fulfill MACRA reporting requirements
- New video shows physicians how to avoid Medicare penalties
- CMS dedicates new webpage to Medicare Beneficiary Identification number change
- Physicians apprehensive regarding requests for provider directory information
- Has a contractor payor stopped paying claims?

- Updated payor profiles for 2017 now available
- The Coding Corner: CMS seeking to simplify E/M documentation guidelines

Noridian/JEMAC, DHCS/MediCal, & Private Payers

Noridian Administrative Services is the Jurisdiction E (JE) *Medicare Administrative Contractor* (MAC). Jurisdiction E includes California. Regularly review postings at the *Noridian/JEMAC* website at med.noridianmedicare.com/web/jeb. Recent updates include:

- MLN Connects Provider eNews *Announcements*—New Medicare Card: Webpage Updates; Hospice Quality Reporting Program: Reconsideration Period Ends August 17; EHR Incentive Program Hardship Exception Application Due by October 1; Chronic Care Management: New Connected Care Videos; Quality Payment Program Hardship Exception Application for 2017 Transition Year Open; Quality Payment Program: Explanation of Special Status Calculation-Correction
- *Claims, Pricers, and Codes*—July 2017 OPPS Pricer File; Part B Billing for Certain New Biosimilar Biological Products before the Modifier is Implemented
- *Publications*—Quality Payment Program 2017: MIPS Quality Performance Category Web-Based Training Course-New; Medicare Secondary Payer Web-based Training Course-Revised; Medicare Secondary Payer Booklet-Revised
- Recovery Audit Program (RAC) Updates
- ASP Medicare Part B Drug Pricing Files and Revisions-October 2017 CR10187
- August Webinars-Register Now

- Medicare B News JE July 2017 Bulletin-Now Available
- New Waived Tests CR10198
- MolDX: DecisionDx-UM (Uveal Melanoma) Final LCD-Effective September 22, 2017
- CMS National Provider Enrollment Conference-September 6 and 7, 2017
- MolDX: Polaris Prostate Cancer Genomic Assay for Men with Favorable Intermediate Risk Disease Final LCD-Effective September 25, 2017

Noridian/JEMAC's Electronic Data Interchange Support Services (EDISS) invites you to subscribe to its e-mail distribution list to receive current information at www.edissweb.com/cgp/news/index.html.

Forthcoming *Noridian/JEMAC* meetings/webinars/workshops include:

- Duplicate Claims (September 13)

Visit med.noridianmedicare.com/web/jeb/education/training-events for more information and to register.

The *Anthem Network Update* (August 2017) is now available online at www11.anthem.com/cal/provider/f5/s3/t3/pw_g314735.pdf and features articles entitled Specialty pharmacy program includes utilization review of clinically equivalent agents as of June 1, 2017; Specialty pharmacy program expands to include utilization review of drug dosage and frequency; and, Reminder: Prior authorization for genetic testing.

UnitedHealthcare's Network Bulletin (August 2017) is now available online at www.unitedhealthcareonline.com > Tools & Resources > News & Network Bulletin and features articles about the new care provider website, enhancements to Link, revamped prior authorization and notification app, and much more.

EDUCATION

[Editor's Note: ANCO organizes clinical and professional education meetings throughout the year and throughout Northern California.]

ANCO's 2017 Professional Education Meeting

ANCO will host its 2017 professional education meeting on September 6th at the *San José Fairmont*. The agenda will include *QPP/MACRA*, *ASCO's COME HOME Project*, *USP797/800*, and *California Legislative/Regulatory Updates*. Download the meeting announcement at www.anco-online.org/ProfEduc2017.pdf.

ANCO's 2017 Hematologic Malignancies Updates

ANCO is organizing a series of *Hematologic Malignancies Updates* in 2017. The second *Update* takes place on September 9th at the *Stanford Park Hotel* with Bruno Medeiros, M.D., *Stanford University*, Charalambos Andreadis, M.D., *University of California, San Francisco*, and Brian Sworder, M.D., *Stanford University*. The latest research on novel treatment modalities for leukemias and lymphomas, along with case studies for these diagnoses will be presented. These updates are supported by *Janssen Biotech*, *Merck*, *Pfizer Oncology*, and *Pharmacyclics*. Download the meeting announcement at www.anco-online.org/3Q2017HemeMalig.pdf.

SAVE THE DATE 18th Multidisciplinary Management of Cancers: A Case-based Approach

The *18th Multidisciplinary Management of Cancers: A Case-based Approach* returns to the *Silverado Resort and Spa* in Napa on March 16-18th. The meeting is sponsored by the *Association of Northern California Oncologists*, *Stanford Cancer Institute*, *UC Davis Comprehensive Cancer Center*, and the *UCSF Helen Diller Family Comprehensive Cancer Center*. Go to www.multicancers.org to register your interest in receiving registration and housing information when it becomes available in the Fall.

Additional Education Meetings

September 8-9th

2017 ASH Meeting on Hematologic Malignancies

ASH

Chicago

(www.hematology.org/Malignancies/Registration.aspx)

September 24-27th

59th Annual Meeting

ASTRO

San Diego

(www.astro.org)

September 26th

*Highlights from the 2017 ASCO Annual Meeting
(Part I of Your Guide to the Latest Cancer Research
and Treatment*

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

September 27-28th

*ASCO Advocacy Summit 2017: Lead, Engage,
Influence*

ASCO

Alexandria

(www.surveymonkey.com/r/AdvocacySummit2017)

September 28th

*Highlights from the 2017 ASCO Annual Meeting
(Part II of Your Guide to the Latest Cancer
Research and Treatment*

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

October 2nd

Treatment Update on Liver Cancer

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

October 4th

*What's New in the Treatment of Waldenstrom's
Macroglobulinemia (WM)*

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

October 5th

Progress in the Treatment of Indolent Non-Hodgkin

Lymphoma

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

October 6th

Update on Soft Tissue Sarcoma

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

October 6-7th

12th Annual Congress: Hematologic Malignancies
NCCN

San Francisco

(www.nccn.org/professionals/meetings/hematological/default.aspx)

Please contact the ANCO office for more information about these meetings.

<p style="text-align: center;">ASSOCIATION & MEMBERSHIP NEWS, RESOURCES, & BENEFITS</p> <p style="text-align: center;"><small>[Editor's Note: All ANCO members are also eligible for several tangible benefits.]</small></p>

Board of Directors

The ANCO *Board of Directors* meets by teleconference and occasionally in person to discuss issues affecting the *Association*, clinical and professional education, and ways to better serve the membership. *Board* teleconferences/meetings are open to individual physician members. The **next regularly scheduled ANCO Board of Directors meeting is scheduled for September 26th**. Please call José Luis González, *ANCO Executive Director*, at (415) 472-3960 if you wish to participate in a future teleconference/meeting.

Individual Member News

The *Conquer Cancer Foundation* (CCF) of the *American Society of Clinical Oncology* (ASCO) is now accepting applications for the 2018 *Young Investigator Award* (YIA). The *Association of Northern California Oncologists* (ANCO) is funding one 2018 YIA for a qualified northern California applicant, and urges all eligible northern California physicians to apply. The YIA is a one-year, \$50,000 grant that provides research funding to promising physicians to

support their transition from final years of training to faculty appointment and to encourage and promote quality research in clinical oncology. Applications in all areas of cancer research are accepted from U.S. and international applicants. For 2018, CCF has dedicated funding for the following areas: breast cancer, northern California researchers, global oncology, kidney cancer, lung cancer, pediatric cancer, sarcoma, and supportive care. Other areas of interest include cholangiocarcinoma, chronic lymphocytic leukemia, gynecological cancers, and melanoma. YIA applications opened on July 1st and are due by 11:50PM ET on September 21st. Eligibility criteria, award details, and the request for proposals are available on the CCF website (www.conquer.org/young-investigator-award). For questions about the YIA or assistance with your application, please e-mail grants@conquer.org.

ASCO urges community oncologists to join ASCO's Leadership Development Program.

Participants in this year-long leadership program will gain extensive exposure to the roles and mission of ASCO, its leadership, and the Society's powerful place in developing the future of cancer care. Visit www.asco.org/training-education/professional-development/leadership-development-program for more information and to apply.

A current *Directory of Members* is available online at www.anco-online.org/pubs.html as a .pdf document. We urge all ANCO members to download their own edition of *The ANCO Directory of Members*. Please verify your *Directory* entry and contact the ANCO office at execdir@anco-online.org with any corrections, additions, and/or deletions.

Group Member News

ANCO initiated a **Group Membership** in 2008 based on a mutual set of perceived values and benefits and a mutual set of interests. The ANCO *Board* believes that the *Association* and *The*

Permanente Medical Group (TPMG) will each receive value from Group Membership.

ANCO initiated a **Multi Site Group Membership** in 2010 to encourage all physicians (medical and radiation oncologists) from multi-site and multidisciplinary practices to join. ANCO thanks *Diablo Valley Oncology & Hematology Medical Group, EPIC Care, Marin Cancer Care, Pacific Cancer Care, and Palo Alto Medical Foundation* for their multi site group memberships.

Institutional Member News

ANCO initiated an **Institutional Membership** in 2002. *Department(s) of Hematology and/or Oncology* of accredited, degree granting teaching universities or research institutions are eligible for institutional membership. ANCO thanks the following Institutional Members for their support:

- *Stanford Cancer Center*
- *University of California, Davis, Cancer Center*
- *University of California, San Francisco*

Corporate Member News

ANCO thanks the following **Corporate Members** for their generous support that enables ANCO to provide services to the hematology/oncology community in northern California, and to provide its members and their patients with substantial benefits in the areas of advocacy, education, and information dissemination:

- AbbVie • Agendia • Alexion Pharmaceuticals
AMGEN • ARIAD Pharmaceuticals
Astellas Oncology • AstraZeneca
Bayer Healthcare Pharmaceuticals
bioTheragnostics
Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb Oncology
Cardinal Health Specialty Solutions
Celgene • Clovis Oncology • Daiichi Sankyo
Eisai • EMD Serono • Exelixis
Foundation Medicine • Genentech BioOncology
Genomic Health • Gilead Sciences
Guardant Health • Helsinn Oncology*

*Heron Therapeutics • Incyte
Janssen Oncology • Jazz Pharmaceuticals
Kite Pharmaceuticals • Lilly Oncology • Merck
nanoString • Novartis Oncology
Oncology Supply/ION • Pfizer Oncology
Pfizer US Biosimilars • Pharmacyclics
Sandoz Biopharmaceuticals • Sanofi Genzyme
Seattle Genetics • Taiho Oncology
Takeda Oncology • Tesaro • TEVA Oncology*

We especially wish to thank and welcome *Agendia, bioTheragnostics, EMD Serono, Kite Pharmaceuticals, and Pfizer US Biosimilars* as new Corporate Members for 2017. *Dendreon, Genoptix Medical Laboratory, GenPath Oncology, Infinity Pharmaceuticals, Ipsen Biopharmaceuticals, Medivation, Merrimack Pharmaceuticals, and Prometheus Laboratories* did not renew their memberships for 2017. Please visit www.anco-online.org/assistance.html for **Corporate Member drug reimbursement and patient assistance program information**. ANCO encourages all member practices to use this resource and enroll all patients at the start of treatment in all available and appropriate patient assistance programs.

AstraZeneca informs ANCO that the *United States Food and Drug Administration* has approved acalabrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

Bristol-Myers Squibb Oncology informs ANCO that the *United States Food and Drug Administration* has approved Opdivo for the treatment of patients 12 years and older with mismatch repair deficient (dMMR) and microsatellite instability high (MSI-H) metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine, oxaliplatin, and irinotecan.

Celgene informs ANCO that the *United States Food and Drug Administration* has approved Idhifa for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.

Jazz Pharmaceuticals informs ANCO that the *United States Food and Drug Administration* has approved Vyxeos, a liposome-encapsulated combination of daunorubicin and cytarabine, for the treatment of adults with newly-diagnosed therapy-related AML (t-AML) or AML with myelodysplastic-related changes (AML-MRC).

Pharmacyclics informs ANCO that the *United States Food and Drug Administration* has approved Imbruvica for the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.

Clinical Trial News

The ASCO Research Community Forum 2017 Annual Meeting is being held on September 24-25th at ASCO. The theme of this year's meeting is advancing cancer care through research partnerships. Register today at www.asco.org/research-progress/research-community-forum/forum-annual-meeting?.

The Summer 2017 edition (as well as past editions) of *Stanford's Clinical Research Newsletter* is now available at cancer.stanford.edu/trials/mdcommunity_newsletter/. This edition focuses on the cutaneous oncology, sarcoma, and developmental therapeutics programs.

UC San Francisco brings the following oncology clinical trials (not previously listed or changed) to the attention of the ANCO membership:

- A Phase Ib and 2a Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX9486 as a Single Agent and in Combination with PLX3397 or Sunitinib in Patients with Advanced Solid Tumors and Patients with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumor (GIST) Who Have Been Previously Treated with Imatinib Mesylate/KIT Directed Tyrosine Kinase Inhibitor (TKI) Therapy (CC#174522). Contact: Jennifer Luan, (415) 514-6220, jenniner.luan@ucsf.edu
- A Phase I, Multicenter, Open-Label Study of Oral Entrectinib (RXDX-101) in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2,

NTRK3, ROS1 or ALK Molecular Alterations (CC#17951). Contact: Kamran Abri Lavasani, (415) 514-6245, kamran.abrilavasani@ucsf.edu

Further information is available at cancer.ucsf.edu/trials.

Publications, Resources, Services, & Surveys

ANCO encourages all members to participate in ASCO's *Practice Census*, the only annual survey of the entire oncology community that aims to capture and describe changes in cancer care and oncology practice over time. Be counted by going to apps.asco.org/oncology-practice-central/survey.

The ASCO Guidelines App is your go-to tool for implementing guideline recommendations into practice. This user-friendly app provides health care providers, patients, and caregivers with the recommended cancer care options for a variety of cancer types. It also includes interactive tools to inform treatment decisions at the point of care, thus increasing the quality of care provided to patients. The app is free to members and nonmembers, kept up to date and will continue to grow as more guidelines and tools are added. Download the app at www.asco.org/guidelines or www.asco.org/apps.

ASCO's *Clinical Affairs Department* is dedicated to providing services, education, and resources to support oncology practices. It offers hands-on assistance in areas such as practice management, quality care assessment and improvement, and efficiency and business intelligence to meet the needs and demands of the current oncology landscape. Resources on the business of oncology, practice management (staffing, technology), practice transformation, and market analysis are available from the *Department*. For more information, visit www.asco.org/practice-guidelines/practice-support.

ASCO is launching its new *Practice Engagement Program* to help administrators, physicians, and other members of the care team navigate ASCO tools, programs, and resources available to help oncology practices respond to the changes

occurring in the cancer care delivery system.

Building on an array of resources developed to help practices remain viable and thrive during this turbulent period, the new *Practice Engagement Team* will help participating practices learn more about the specific ASCO services and programs that can best support their needs. Learn more at www.asco.org/advocacy-policy/asco-in-action/new-practice-engagement-program-connects-practices-specific-resources.

ASCO's PracticeNET is a collaborative network in which practices share and receive insights to enhance their business operations and quality of care. PracticeNET is the first initiative of ASCO's *Clinical Affairs Department*. This new initiative uses existing data from your practice management system to offer customizable reports that measure practice-wide and individual performance against a national database of other PracticeNET participants. Go to www.asco.org/PracticeNET for more information.

ASCO and *Innovative Oncology Business Solutions (IOBS)* have announced a new collaboration, ASCO COME HOME—an oncology medical home program designed to transition community oncology practices from volume-based to value-based care by structuring reimbursement around the full range of services needed by patients with cancer. ASCO COME HOME will also prepare oncology practices for full implementation of the Quality Payment Program under MACRA. ASCO is currently accepting practices for the fee-based program. For more information, please visit www.asco.org/practice-guidelines/practice-support/asco-consulting-services/asco-come-home.

ACCC and the *Advisory Board Oncology Roundtable* are collaborating on a comprehensive survey to explore the challenges and successes of cancer programs across the country. The *Trending Now in Cancer Care* survey examines the hottest topics in oncology care today, including hospital and physician alignment strategies, value-based care models, EHR use and

interoperability, clinical staffing challenges, and more! The survey is now open but will close on August 21st. Take the survey at www.accc-cancer.org/surveys/CancerProgramTrends-2017.asp.

ACCC's online *Oncology Drug Database* provides quick access to information on oncology drug coding, billing, and reimbursement at www.accc-cancer.org/drugdatabase/.

ACCC's enhanced set of *Financial Advocacy Network* resources are at www.accc-cancer.org/resources/FinancialAdvocacy-Overview.asp. This "one-stop" destination for comprehensive financial advocacy information includes online training materials, practical financial advocacy tools, peer-to-peer networking, and more.

The cost of cancer care continues to be a top concern for patients and their healthcare providers. In response, ACCC has launched *The Financial Advocacy Boot Camp*, the first free online training program designed for all those who work to assist cancer patients in navigating financial issues related to their cancer treatment. Learn more at www.accc-cancer.org/resources/FinancialAdvocacy-bootcamp.asp.

ACCC's 2017 *Patient Assistance and Reimbursement Guide* is an essential tool for cancer program staff to use in helping patients with issues related to the cost of treatment and in meeting reimbursement challenges. The *Guide* features a list of pharmaceutical and non-pharmaceutical patient assistance programs (PAPs), including directions on how to apply and links to enrollment forms. Visit www.accc-cancer.org/publications/pdf/Patient-Assistance-Guide-2017.pdf to access this resource. In addition, ACCC has developed a tool for accessing patient assistance and reimbursement programs for use on a desktop, table, or mobile device. The *Financial Advocacy Network* (FAN) app is available at accc-fan-app.org. ***assistPoint* is your website for complimentary one-stop cancer Patient Assistance.** You can search by generic,

brand name, manufacturer, or diagnosis for the enrollment forms you need; get enrollment form PDFs for cancer drugs; get NDC numbers for all of those drugs; find the HCPCS J-code for each drug; get coding and billing guidelines for many drugs; and, learn more about the drugs you give. Go to www.assistpoint.com to learn more.

NCCN has published and/or updated their *Chemotherapy Order Templates, Clinical Practice Guidelines in Oncology, Drugs & Biologics Compendium, Evidence Blocks, Guidelines for Patients, Imaging Appropriate Use Criteria, and/or Radiation Therapy Compendium* for acute lymphoblastic leukemia (V1.2017), adolescent and young adult oncology (V1.2018), esophageal and esophagogastric cancer (V2.2017), gastric cancer (V2.2017), genetic/familial high-risk assessment: colorectal (V2.2017), kidney cancer (Spanish, V1.2017), lung cancer screening (V2.2018), malignant pleural mesothelioma (V2.2017), myeloproliferative neoplasms (V1.2018), neuroendocrine tumors (V3.2017), non-small cell lung cancer (V8.2017), survivorship (V2.2017). Go to www.nccn.org for more information. NCCN is pleased to offer pocket-sized versions of the NCCN *Clinical Practice Guidelines in Oncology* for a number of their guidelines at www.nccn.org/redirects/nicelines.asp?Type=general.